Infinity Bio Funding & Investors
Baltimore, MD
Infinity Bio is a Circulating Antibody Repertoire Profiling service company, leveraging a novel technology, MIPSA (Molecular Indexing of Proteins (or Peptides) by Self Assembly) developed by Dr. H. Ben Larman, a pioneer in this field. Our various antigen libraries provide cost effective, comprehensive and quantitative analyses of antibody responses to infections, vaccinations, self-antigens and allergens. Our proprietary method allows for the rapid and flexible content customization. Infinity Bio can design and create customer specific peptide libraries against any target of choice.
infinitybio.comTotal Amount Raised: $4,516,093
Infinity Bio Funding Rounds
Seed
$4,516,093
Funding info provided by Diffbot.